Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871153 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Greg Durm, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03871153: Clinical Trial Phase 2 study, sponsored by Greg Durm, MD.
NCT03871153 is a Phase 2 study that was terminated before completion, run by Greg Durm, MD. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03871153, a Phase 2 study, was terminated before completion, sponsored by Greg Durm, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction therapy. After surgical resection, all patients who remain eligible will be treated with adjuvant Durvalumab every 4 weeks for 6 cycles beginning 4-12 weeks after surgical resection.
Primary Outcome
Pathologic Complete Response Rate is defined as lack of evidence of viable cancer in the surgical specimen at the time of surgery.
Interventions
- DRUG Carboplatin
- PROCEDURE Surgical Resection
- DRUG Paclitaxel
- RADIATION Radiation
- DEVICE Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Why NCT03871153 stopped before completion
NCT03871153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03871153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03871153 about?
NCT03871153 is a clinical study titled "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer". This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction t...
What is the current status of trial NCT03871153?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-08-02. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03871153?
The interventions under investigation include: Carboplatin (DRUG), Surgical Resection (PROCEDURE), Paclitaxel (DRUG), Radiation (RADIATION), Durvalumab (DEVICE).
Who is sponsoring clinical trial NCT03871153?
This trial is sponsored by Greg Durm, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03871153's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI